Search clinical trials for: Iron Chelating Agents

Total 188829 results

University Hospital, Bordeaux

Recruiting

Iron Chelation in the Prevention of Secondary Degeneration After Stroke (CHEL-IC)

Stroke

France
Germans Trias i Pujol Hospital
Fundació Institut Germans Trias i Pujol

Completed

Thrombolysis and Deferoxamine in Middle Cerebral Artery Occlusion (TANDEM-1)

Ischemic Stroke, Acute

Spain
Hospices Civils de Lyon

Unknown

Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (GREFFE)

Myelodysplastic Syndromes | Myeloid Leukemia

France
ApoPharma

Completed

Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration (TIRCON-EXT)

Pantothenate Kinase-Associated Neurodegeneration

United States, Germany, Italy, United Kingdom
ApoPharma

Terminated

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Iron Overload | Sickle Cell Disease | Other Anemias

United States, United Kingdom, Egypt, Canada, Saudi Arabia
Aditya S. Pandey, MD
Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research

Recruiting

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH) (DISH)

Aneurysmal Subarachnoid Hemorrhage

United States, China
Hesham Al-Inany

Unknown

Use of Desferal for Prevention of ARDS in Hospitalised Cases Documented With Covid 19 Infection

Covid 19
HealthCore-NERI
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Heart Diseases | Cardiovascular Diseases | Beta-Thalassemia

United States
ApoPharma

Completed

Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

Sickle Cell Disease

Canada
Ospedale Microcitemico
Azienda Sanitaria Locale di Cagliari

Completed

Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major (DFODFPTM)

Iron Overload | Cardiomyopathy

Italy
Ain Shams University

Unknown

Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial

Iron Deficiency Anemia

Egypt
University of Pisa
IRCCS Burlo Garofolo; University of Genova

Recruiting

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Iron Overload

Italy
Novartis Pharmaceuticals

Completed

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Transfusion-dependent Anemia

Egypt, Hungary, Turkey, United States, Bulgaria, Italy, Belgium, Russian Federation, Philippines, France, Malaysia, India, Oman, Panama, Lebanon, Thailand, Tunisia
University Hospital, Lille
European Commission; ApoPharma

Completed

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII)

Parkinson Disease

Netherlands, Spain, France, Portugal, Czechia, United Kingdom, Austria, Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload (HYPERION)

Cardiac Iron Overload

Taiwan, Egypt, Thailand, Turkey, United Kingdom, Italy, Canada, Greece
Novartis Pharmaceuticals

Completed

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Anemia, Sickle Cell

United States
ApoPharma

Completed

Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers

Healthy

Canada
Lipomed

Completed

Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients

Hemochromatosis

Egypt, Turkey
Weill Medical College of Cornell University

Unknown

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Thalassemia

United States
ApoPharma
Food and Drug Administration (FDA)

Completed

Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)

Pantothenate Kinase-Associated Neurodegeneration

United States, Germany, Italy, United Kingdom
Shire

Withdrawn

Treatment of Iron Overload Requiring Chelation Therapy

Metabolic Diseases | Iron Metabolism Disorders | Iron Overload | Beta-thalassemia | Transfusional Hemosiderosis | Transfusional Iron Overload | Iron Chelation
Beth Israel Deaconess Medical Center
Medical University of South Carolina; Johns Hopkins University; Massachusetts... and other collaborators

Completed

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Intracerebral Hemorrhage

United States, Canada
Children's Hospital of Philadelphia
Ann & Robert H Lurie Children's Hospital of Chicago; The Cooley's Anemia Foundation...

Completed

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Thalassemia Major With Severe Transfusional Iron Overload

United States
ApoPharma

Completed

A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers

Healthy Volunteers

Canada
Swiss Federal Institute of Technology

Completed

Iron Absorption From Tef-injera in Women of Reproductive Age

Iron Deficiency

Switzerland
Lipomed

Completed

Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients

Hemochromatosis

Switzerland
Novartis Pharmaceuticals

Completed

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Iron Overload | Sickle Cell Disease | Hemolytic Anemia

United States, Canada
University of Toronto
Canadian Institutes of Health Research (CIHR); Canadian Diabetes Association; The Physicians' Services Incorporated Foundation and other collaborators

Unknown

Meta-analyses of the Effect of 'Catalytic' Doses of Fructose and Its Epimers on Carbohydrate Metabolism

Obesity | Overweight | Metabolic Syndrome | Type 2 Diabetes | Prediabetes | Dysglycemia

Canada
University of Erlangen-Nürnberg Medical School
Novartis Pharmaceuticals

Terminated

Exjade-Early-Trial

Myelodysplastic Syndromes

Germany
Novartis

Completed

Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

Healthy
Neuroscience Trials Australia
The Florey Institute of Neuroscience and Mental Health

Active, not recruiting

Deferiprone to Delay Dementia (The 3D Study)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's Disease

Australia
Consorzio per Valutazioni Biologiche e Farmacologiche
European Commission

Completed

Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients

Chronic Iron Overload

Italy, United Kingdom, Egypt, Greece, Cyprus, Albania, Tunisia
SocraTec R&D GmbH
SocraMetrics GmbH

Completed

Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration

Bioequivalence

Germany
Sun Yat-sen University

Recruiting

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

China
University of New Mexico

Recruiting

Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation

DNA Damage | Immune System Disorder

United States
Abderrahmane Mami Hospital
Eshmoun Clinical Research Center; Datametrix

Unknown

Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia (TRONCHER)

COVID19 | Intensive Care Unit

Tunisia
ApoPharma

Completed

Efficacy Study in Removing Excess Iron From the Heart

Hemosiderosis | Thalassemia Major

Greece, Italy
Aswan University Hospital

Recruiting

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

Brain Ischemia

Egypt
Novartis Pharmaceuticals

Completed

Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload (EXCALIBUR)

Chronic Iron Overload

Germany
Novartis Pharmaceuticals

Completed

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet (Jupiter)

Non-transfusion-dependent Thalassemia | Transfusion-dependent Thalassemia

Egypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam
Imperial College London

Completed

A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease (DeferipronPD)

Parkinson's Disease

United Kingdom
St. John's Research Institute
Ministry of Science and Technology, India; Akzo Nobel

Completed

Effect of Iron Fortified Wheat Flour on Cognition and Iron Status in Indian School Children

Iron Deficiency Anemia | Iron Deficiency | Cognition

India
DisperSol Technologies, LLC

Completed

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Thalassemia Major

Thailand, United States
ApoPharma

Terminated

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias (FIRST)

Iron Overload | Sickle Cell Disease | Other Anemias

United States, Turkey, United Kingdom, Egypt, Saudi Arabia, Brazil, Canada, Tunisia
National Institute of Diabetes and Digestive and...

Completed

Combination Iron Chelation Therapy

Iron Overload | Thalassemia

United States
Duke University

Active, not recruiting

Ferritin and Iron Burden in SAH sIRB

Dementia | SAH

United States
Wageningen University
Nestlé Foundation; Noguchi Memorial Institute for Medical Research

Completed

Improving Iron Status Through Consumption Of Iron Fortified Cowpea: An Intervention Study

Anemia | Low Iron Stores

Ghana
Novartis Pharmaceuticals

Completed

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)

Myelodysplastic Syndromes

China, Hong Kong, Switzerland, United Kingdom, Italy, Thailand, Bulgaria, Greece, Russian Federation, Canada, Mexico, Australia, Denmark, Malaysia, New Zealand, United States
Ain Shams University

Unknown

Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)

Beta-thalassemia | Serum Ferritin | Iron Chelation Therapy

Egypt
Ain Shams University

Unknown

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Sickle Cell Disease | Beta-thalassemia Major | Iron Hemosiderosis

Egypt

Search clinical trials for: Iron Chelating Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations